These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7910040)

  • 1. Recombinate study.
    Gomperts E
    Ann Hematol; 1994; 68 Suppl 3():S51. PubMed ID: 7910040
    [No Abstract]   [Full Text] [Related]  

  • 2. A 3.5-year study of immune function in persons with hemophilia infusing recombinant factor VIII.
    Brettler D
    Ann Hematol; 1994; 68 Suppl 3():S49-50. PubMed ID: 7910039
    [No Abstract]   [Full Text] [Related]  

  • 3. Changes in CD4 count relative to product usage: findings from the transfusion safety study.
    Hilgartner MW
    Semin Hematol; 1993 Oct; 30(4 Suppl 5):7-9. PubMed ID: 7903481
    [No Abstract]   [Full Text] [Related]  

  • 4. Hemofil-M study.
    Rocino A; de Biasi R
    Ann Hematol; 1994; 68 Suppl 3():S55-7. PubMed ID: 7910042
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group.
    Mannucci PM; Brettler DB; Aledort LM; Lusher JM; Abildgaard CF; Schwartz RS; Hurst D
    Blood; 1994 Apr; 83(7):1958-62. PubMed ID: 7908234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of clinical studies of recombinant factor VIII (recombinate) in patients with hemophilia A. Recombinate Study Group.
    Bray GL
    Transfus Med Rev; 1992 Oct; 6(4):252-5. PubMed ID: 1421824
    [No Abstract]   [Full Text] [Related]  

  • 7. Beriate-P study.
    Gringeri A
    Ann Hematol; 1994; 68 Suppl 3():S53-4. PubMed ID: 7910041
    [No Abstract]   [Full Text] [Related]  

  • 8. Changes in T4/T8 ratio over a ten years period related to the factor VIII concentrates used in a group of HIV negative haemophiliacs.
    Smid WM; van der Meer J; Halie MR
    Thromb Haemost; 1995 Mar; 73(3):552-3. PubMed ID: 7667844
    [No Abstract]   [Full Text] [Related]  

  • 9. Monoclate-P--hemofil-M study.
    Seremetis S
    Ann Hematol; 1994; 68 Suppl 3():S45-7. PubMed ID: 7910038
    [No Abstract]   [Full Text] [Related]  

  • 10. Very-high-purity versus intermediate-purity factor VIII in human immunodeficiency virus-positive hemophiliacs: conclusions of a prospective 3-year study. Monoclate Study Group.
    Seremetis SV
    Semin Hematol; 1993 Oct; 30(4 Suppl 5):10-3. PubMed ID: 7903480
    [No Abstract]   [Full Text] [Related]  

  • 11. Who should use recombinant factor VIII?
    Hoots K
    Ann Hematol; 1994; 68 Suppl 3():S65-8. PubMed ID: 8180258
    [No Abstract]   [Full Text] [Related]  

  • 12. Summary of clinical experience with recombinant factor VIII products--Recombinate.
    White GC
    Ann Hematol; 1994; 68 Suppl 3():S7-8. PubMed ID: 8180260
    [No Abstract]   [Full Text] [Related]  

  • 13. A longitudinal study of immunological status in Chinese haemophiliacs: importance of the heat viral inactivation of factor concentrates. II. Improvements of CD4/CD8 ratio after treatments with heat-inactivated factor concentrates.
    Shen MC; Hu FC; Lin JS; Tsai W; Fon MF; Wang EC
    Haemophilia; 1998 Jan; 4(1):33-40. PubMed ID: 9873863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purity of factor VIII concentrates.
    Goudemand J; Parquet-Gernez A; Goudemand M
    Blood Coagul Fibrinolysis; 1993 Jun; 4(3):499-500. PubMed ID: 8329577
    [No Abstract]   [Full Text] [Related]  

  • 15. Immune tolerance in hemophilia and the treatment of hemophiliacs with an inhibitor. Proceedings of a meeting. Palermo, Italy, October 1999.
    Haematologica; 2000 Oct; 85(10 Suppl):1-116. PubMed ID: 11236744
    [No Abstract]   [Full Text] [Related]  

  • 16. Induction of immune tolerance with factor VIII concentrate in patients with hemophilia A and inhibitors.
    Ewing NP
    Prog Clin Biol Res; 1990; 324():59-68. PubMed ID: 2106693
    [No Abstract]   [Full Text] [Related]  

  • 17. Recombinant clotting factors in the treatment of hemophilia.
    Lee C
    Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term surveillance studies of previously untreated and treated patients, virally uninfected and infected patients--impact on the immune and other systems.
    Poon MC
    Ann Hematol; 1994; 68 Suppl 3():S83-6. PubMed ID: 7910044
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune reconstitution inflammatory syndrome (IRIS) as a cause for inhibitor development in hemophilia.
    Werwitzke S; Tiede A; Stoll M; von Depka M
    J Thromb Haemost; 2004 Jan; 2(1):193-4. PubMed ID: 14717985
    [No Abstract]   [Full Text] [Related]  

  • 20. Prospective clinical trial of high-purity factor VIII preparations in haemophiliacs.
    Varon D
    Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S82-3. PubMed ID: 7495975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.